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Summary Immunohistochemical staining of bcl-2 and p53 proteins was compared with thymidine labelling index (TLI) and cell loss factor (0)
in lung cancer. Neither bcl-2 nor p53 overexpression was associated with high cell loss but strong bcl-2 staining was associated with higher
TLI. Concomitant strong p53 and bcl-2 expression, not the usual inverse relationship, plus high cell-loss factor was present in three
neuroendocrine carcinomas. Other factors presumably have a role in controlling cell death in these tumours.
Keywords: lung carcinoma; neuroendocrine; thymidine labelling index; cell loss factor; bcl-2; p53; apoptosis; immunohistochemistry
Apoptosis is a major mechanism oftumour cell loss, itselfa major
determinant of tumour growth rate, and the protein products of
both thep53 and bcl-2 genes have a role in this process. The func-
tions ofboth these genes and their relationship to other regulatory
proteins has been extensively reviewed (Lane, 1993; Piepentol and
Vogelstein, 1993; Lu et al, 1996; Yang and Korsmeyer, 1996).
In an earlier study (Kerr and Lamb, 1984), we derived data on
cell proliferation and cell loss in 17 human lung tumours. Tumour
thymidine labelling index (TLI) was measured in vitro and, using
recognized methods and formulae (Collins et al, 1956; Steel
1967), a cell loss factor (0) was calculated. Cell loss factor
expresses the proportion ofcells being lost from apopulation rela-
tive to the number being added to itby mitotic activity. Thus a cell
loss factor of0.90 implies that for every 100 cells being added to a
population by mitosis, 90 are lost by whatever means.
Inthis study, weinvestigate therelationshipbetweenthe cellprolif-
eration/loss datainthese 17 humanlung tumours andtheirexpression
ofthep53 and bcl-2 genes assessed immunohistochemically.
MATERIALS AND METHODS
The histological classification of the tumours required revision of
the original (Kerr and Lamb, 1984). 'Large-cell carcinoma with
stratification' is now classified as poorly differentiated squamous
carcinoma. One tumour, thought originally to be a metastatic
deposit of large-cell carcinoma, now, with follow-up, fulfils
criteria of a primary large-cell neuroendocrine cancer. Thirteen of
the cases were typical bronchogenic carcinomas (six squamous,
three adenocarcinoma, two small-cell undifferentiated, one large-
cell neuroendocrine and one large-cell undifferentiated carci-
noma). Two were renal cell carcinoma metastases and one a
primary clear cell carcinoma.
Tumour thymidine labelling index (TLI) was obtained by in
vitro incubation of tumour fragments with tritiated thymidine
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under hyperbaric oxygenation. Labelled cells were visualized and
counted on autoradiographs of tissue sections (Kerr et al, 1983).
Actual growth rate or doubling time (DT) was calculated from
measurements made on serial chest radiographs using Collins
graphic method (Collins et al, 1956). Knowledge of the tumour
cell population TLI allows the potential doubling time (DTpot) to
be estimated. From DT and DTpot data, the cell loss factor (0)
was calculated (Steel, 1967).
In this current study, paraffin-embedded tissue sections were
mounted on APES-coated slides and dried at 56°C for 30 min.
Dewaxing, blocking endogenous peroxidase activity, and micro-
wave antigen retrieval then followed (King 1994).
Prepared sections were stainedusing monoclonal antibodies Do7
and 124 (Dakopatts, Copenhagen) raised against p53 and bcl-2
Table 1 Tumour histology, [3H]thymidine labelling index, tumour cell loss
factor, p53 and bcl-2 staining
Case Cell TLI(%) Cell loss p53 bcl-2
type factor score score
1 LCU 23.0 0.99 .-
2 SCU 22.5 0.98 ++
3 LCNE 22.2 0.99 ... ...
4 SCU 20.3 0.90 ... ...
5 PDSQ 20.0 0.95 + ++
6 PDSQ 19.7 0.93 - -
7 PDSQ 18.7 0.97 + -
8 MDSQ 16.2 0.95 ++ -
9 WDAD 10.3 0.79 + -
10 PDAD 10.2 0.95 +++ -
11 PDSQ 8.5 0.71 + -
12 PDSQ 6.2 0.91 +++ +
13 PDAD 5.6 0.85 ... +
14 2°RCC 3.7 0.85 + -
15 1 0CC 2.9 0.76 +++ ...
16 2°RCC 0.7 0.54 ++ +
TLI, thymidine labelling index; LCU, large-cell undifferentiated; LCNE, large-
cell neuroendocrine; SCU, small-cell undifferentiated; SO, squamous; AD,
adenocarcinoma; PD, MD and WD, poorly, moderately and well-
differentiated respectively; 2°RCC, metastatic renal cell; 1 0CC, primary clear
cell; cell loss factor - see text.
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proteins and used at dilutions of 1:200 and 1:50 respectively.
Primary bound antibody was detected using a standard sABC tech-
nique, visualized with diaminobenzidene (DAB). Appropriate
known positive controls were used throughout this study.
Assessment was made of staining intensity and staining was
graded as focal if < 5% of tumour cells were positive, moderate
(5-70% positive) or abundant (> 70% positive).
RESULTS
Of the 17 original cases studied, archival tumour tissue was avail-
able in 16 cases. The results are presented in Table 1. Some of
these data on TLI and cell loss factor have already been published
(Kerr and Lamb, 1984).
Ten of sixteen (62.5%) tumours exhibited moderate (3/10) or
abundant (7/10) staining for p53 protein. Five ofthe sixteen (31%)
tumours showed moderate (1/5) or abundant (4/5) staining with
anti-bcl-2. In three cases (16%), only very weak and focal staining
was found. All four cases that had strong abundant staining for
bcl-2, expressed p53 moderately or strongly. Three of these four
cases were primary undifferentiated lung carcinomas exhibiting
neuroendocrine features. The fourth case was a rather uncommon
primary clear cell carcinoma. One large-cell undifferentiated
carcinoma (without neuroendocrine features) expressed p53
protein strongly but was negative for bcl-2. Of the differentiated
primary lung carcinomas, excluding case 5, bcl-2 staining was
negative or weak whereas p53 staining was recorded at all grades.
Within the group oftypical lung cancers (Cases 1-13), the mean
cell loss factor for the relatively high-p53 group (+++/++, n = 8)
was 0.94 and, although this was greater than that for the low-p53
group (+/-, n = 5, mean 0 = 0.87), this was not significantly
different. Similarly, mean cell loss was not significantly different
between the high-bcl-2 group (+++/++, n =4, mean 0 = 0.96) and
the low-bcl-2 group (+/-, n = 9, mean 0 = 0.89). Using the same
groupings, mean TLI was almost identical between the two levels
ofp53 expression (high p53, mean TLI 15.8%; low p53, mean TLI
15.4%). However, the four cases with high bcl-2 expression had a
significantly higher TLI (21.25%) than the low-bcl-2 group
(13.1%) (P = 0.03) (student's t-test).
DISCUSSION
Tumours grow as a result of excess cell proliferation and a relative
reduction in cell loss, one of the most important mechanisms for
which is tumour cell apoptosis. Various methods, including thymi-
dine labelling indices, have been used to measure cell proliferation
(Hall and Levison, 1990).
The protein product of the bcl-2 proto-oncogene suppresses
apoptosis (Yang and Korsmeyer, 1996). Overexpression may facil-
itate oncogenesis by keeping alive mutated cells that would
normally die. Besides lymphomas, increased bcl-2 expression also
occurs in solid tumours, including lung carcinomas (Pezzella et al,
1993; Ikegaki et al, 1994). p53 protein induces growth arrest in
cells to allow DNA repair or, in the case of irreparable damage, it
may induce apoptosis (Lane, 1993.) Gene mutation or post-tran-
scriptional alteration, as well as leading to loss of function, also
leads to intranuclear protein accumulation and detectability in an
immunohistochemical system such as the one used in this study. It
is probable that mutations or deletions ofeither thep53 and/or bcl-
2 genes upset normal proliferative and apoptotic mechanisms
within cell populations, promoting the malignant phenotype.
In a previous study (Kerr and Lamb, 1984), we showed that cell
loss was greater in tumours with a higher proliferation rate and
those which were poorly differentiated (see Table 1). It was clearly
of interest to see if, in this small group of tumours with unique
data, these were related to bcl-2 or p53 protein levels.
Most tumours showed stainable p53 protein, independent of
TLI; this is in contrast to a reported positive correlation between
p53 expression and PCNA-determined cell proliferation index in
lung cancer (Wiethege et al, 1995). PCNA expression in tumours
is, however, known to be an unreliable measure of proliferative
activity (Coltrera et al, 1993). In breast carcinoma, little correla-
tion between p53 expression and tumour TLI was found
(Silvestrini et al, 1994). Our relationship between high TLI and
excess bcl-2 differs from Park et al (1995) who used flow cyto-
metric proliferation data on non-small-cell lung cancers. Data
relating p53 and bcl-2 to cell proliferation are scarce and inconclu-
sive. More studies are needed to reach a meaningful conclusion.
High levels of, presumably non-functional, p53 should limit
apoptosis and reduce tumour cell loss. Tumours with high p53
levels have more cell loss than cancers with low p53 levels. This
was not, however, statistically significant in the small number of
cases available for study. A similar trend (not statistically signifi-
cant) with bcl-2 levels (high bcl-2 with high cell loss) was also
against expectations. High bcl-2 levels, assuming maintainance
of the protein's function, should suppress apoptosis and diminish
cell loss.
In this study, most non-small-cell carcinomas tended to show
negative or weak staining for bcl-2. In strongly positive tumours,
staining was homogeneous. Pezzella et al (1993) documented bcl-
2 positivity in 25% of squamous cell carcinomas and noted homo-
geneous staining but did not comment on staining intensity. Of
interest was the strong bcl-2 staining in the three neuroendocrine
tumours (two small-cell and one large-cell type), which were asso-
ciated with high cell-loss factors, and one lesion ofclear cell carci-
noma. The overexpression ofbcl-2 in small-cell carcinomas seems
contradictory in a tumour characterized by prominent apoptosis
and a high cell loss factor but frequent overexpression ofbcl-2 in
lung small-cell carcinoma has already been reported (Ben-Ezra et
al, 1994; Jiang et al, 1995).
We found that excess bcl-2 expression correlated with strong
p53 staining, primarily in tumours of neuroendocrine type. In our
non-neuroendocrine group, mutually exclusive staining was
observed in only two tumours (cases 1 and 10) but was relatively
exclusive in three others (cases 8, 12 and 13). These results mirror
the inverse relationship between p53 and bcl-2 expression found
in breast (Leek et al, 1994; Silvestrini et al, 1994) and thyroid
(Pilotti et al, 1994) carcinoma. This may be explained by the
down-regulation of bcl-2 expression by p53 via a negative
response element on the bcl-2 gene (Miyashita et al, 1994a).
However, at least in lung tumours of neuroendocrine origin,
mutant p53 may not be able to down-regulate the bcl-2 gene.
These genes are known to function differently in different tumour
types (Pietenpol et al, 1994).
Excess bcl-2 expression may promote the malignant phenotype
by suppressing apoptosis (Lu et al, 1996). Mutation of p53 may
have the same effect, facilitating unopposed cell proliferation.
Both these abnormalities may have a compounding effect on the
progression of neoplasia. This concurs with the known clinical
behaviour of neuroendocrine, particularly small-cell, lung carci-
noma. Such combined expressin may interfere with the control of
cell death in a tumour (Miyashita et al, 1994b).
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Immunohistochemically demonstrated excess p53 protein may
not necessarily reflect gene mutation (Hall and Lane, 1994). bcl-2
gene mutation may also lead to a functionally inactive protein
product, which may still be detectable by immunohistochemistry.
The existence of Bax and related proteins further compounds the
issue When overexpressed, Bax counteracts bcl-2 (Yin et al,
1994). It may be important to determine cellular levels of Bax. If
Bax levels are low, even low levels of bcl-2 may be sufficient to
rescue a cell from apoptosis. If, however, Bax is abundant a cell
may be more vulnerable to a (p53-mediated?) signal to die and
thus require high levels of functional bcl-2 to save it (Yin et al,
1994). Perhaps in lung neuroendocrine carcinoma, Bax levels are
also very high.
This is a complex issue involving many inter-related factors,
some of which cannot, as yet, be measured in material such as
ours. It seems likely that cell death control may vary between
tumours. This may have implications when chemoresponsiveness
in small-cell lung cancer is considered.
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